Bisphosphonate-associated osteonecrosis of the jaw;Bisphosphonat-assoziierte osteonekrosen des kieferknochens

Wiener Klinische Wochenschrift

Volumn 120, Issue 15-16, 2008, Pages 467-476

  Krauth, Maria Theresa ^a   Fügl, Alexander ^a   Gruber, Reinhard ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Alveolar bone; Bisphosphonates; Bone metastasis; Multiple myeloma; Osteonecrosis; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

ALVEOLAR BONE; BONE METASTASIS; BONE NECROSIS; BREAST METASTASIS; CLINICAL TRIAL; DENTAL CARE; DRUG EFFICACY; DRUG INDUCED DISEASE; HUMAN; JAW; MONOTHERAPY; MULTIPLE MYELOMA; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; PROGNOSIS; PROSTATE CANCER; REVIEW; WOUND HEALING IMPAIRMENT;

DIPHOSPHONATES; HUMANS; INJECTIONS, INTRAVENOUS; JAW DISEASES; OSTEONECROSIS;

EID: 54749128523     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-008-1002-9     Document Type: Review

References (74)

1. Djulbegovic B, Wheatley K, Ross J, Clark O, Bos G, Goldschmidt H, Cremer F, Alsina M, Glasmacher A (2002) Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev CD003188
2. MD Michaelson MR Smith 2005 Bisphosphonates for treatment and prevention of bone metastases J Clin Oncol 23 8219 8224
3. Yuen KK, Shelley M, Sze WM, Wilt T, Mason MD (2006) Bisphosphonates for advanced prostate cancer. Cochrane Database Syst Rev CD006250
4. Pavlakis N, Schmidt R, Stockler M (2005) Bisphosphonates for breast cancer. Cochrane Database Syst Rev CD003474
5. A Ibrahim N Scher G Williams R Sridhara N Li G Chen J Leighton B Booth JV Gobburu A Rahman Y Hsieh R Wood D Vause R Pazdur 2003 Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases Clin Cancer Res 9 2394 2399
6. SB Woo JW Hellstein JR Kalmar 2006 Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws Ann Intern Med 144 753 761
7. SL Ruggiero B Mehrotra TJ Rosenberg SL Engroff 2004 Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases J Oral Maxillofac Surg 62 527 534
8. RE Marx Y Sawatari M Fortin V Broumand 2005 Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment J Oral Maxillofac Surg 63 1567 1575
9. CR Dunstan D Felsenberg MJ Seibel 2007 Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease Nat Clin Pract Oncol 4 42 55
10. CA Migliorati MA Siegel LS Elting 2006 Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment Lancet Oncol 7 508 514
11. SL Ruggiero J Fantasia E Carlson 2006 Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102 433 441
12. T Van den Wyngaert MT Huizing JB Vermorken 2007 Osteonecrosis of the jaw related to the use of bisphosphonates Curr Opin Oncol 19 315 322
13. JP Bilezikian 2006 Osteonecrosis of the jaw - do bisphosphonates pose a risk? N Engl J Med 355 2278 2281
14. C Hewitt CS Farah 2007 Bisphosphonate-related osteonecrosis of the jaws: a comprehensive review J Oral Pathol Med 36 319 328
15. CD Krueger PM West M Sargent AE Lodolce AS Pickard 2007 Bisphosphonate-induced osteonecrosis of the jaw Ann Pharmacother 41 276 284
16. R Gutta PJ Louis 2007 Bisphosphonates and osteonecrosis of the jaws: science and rationale Oral Surg Oral Med Oral Pathol Oral Radiol Endod 104 186 193
17. M Pazianas P Miller WA Blumentals M Bernal P Kothawala 2007 A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics Clin Therap 29 1548 1558
18. A Bamias E Kastritis C Bamia LA Moulopoulos I Melakopoulos G Bozas V Koutsoukou D Gika A Anagnostopoulos C Papadimitriou E Terpos MA Dimopoulos 2005 Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors J Clin Oncol 23 8580 8587
19. MA Dimopoulos E Kastritis A Anagnostopoulos I Melakopoulos D Gika LA Moulopoulos C Bamia E Terpos K Tsionos A Bamias 2006 Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid Haematologica 91 968 971
20. K Zervas E Verrou Z Teleioudis K Vahtsevanos A Banti D Mihou D Krikelis E Terpos 2006 Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients Br J Haematol 134 620 623
21. P Tosi E Zamagni D Cangini P Tacchetti F Di Raimondo L Catalano A D'Arco S Ronconi C Cellini M Offidani G Perrone M Ceccolini A Brioli S Tura M Baccarani M Cavo 2006 Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone Blood 108 3951 3952
22. A Wutzl G Eisenmenger M Hoffmann C Czerny D Moser P Pietschmann R Ewers A Baumann 2006 Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients Wien Klin Wochenschr 118 473 478
23. BM Clarke J Boyette E Vural JY Suen EJ Anaissie BC Stack Jr 2007 Bisphosphonates and jaw osteonecrosis: the UAMS experience Otolaryngol Head Neck Surg 136 396 400
24. C Walter KA Grotz M Kunkel B Al-Nawas 2007 Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis Support Care Cancer 15 197 202
25. RE Marx JE Cillo Jr JJ Ulloa 2007 Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment J Oral Maxillofac Surg 65 2397 2410
26. RA Kyle GC Yee MR Somerfield PJ Flynn S Halabi S Jagannath RZ Orlowski DG Roodman P Twilde K Anderson 2007 American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma J Clin Oncol 25 2464 2472
27. (2007) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65: 369-376
28. E Shane S Goldring S Christakos M Drezner J Eisman S Silverman D Pendrys 2006 Osteonecrosis of the jaw: more research needed J Bone Miner Res 21 1503 1505
29. (2006) Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc 137: 1144-1150
30. MQ Lacy A Dispenzieri MA Gertz PR Greipp Kl Gollbach SR Hayman S Kumar JA Lust V Rajkumar SJ Russell TE Witzig SR Zeldenrust D Dingli L Bergsagel R Fonseca CB Reeder K Stewart V Roy RJ Dalton AB Carr D Kademani EE Keller CF Viozzi RA Kyle 2006 Mayo Clinic Consensus Statement for the Use of Bisphosphonates in Multiple Myeloma Mayo Clin Proc 81 1047 1053
31. S Khosla D Burr J Cauley DW Dempster PR Ebeling D Felsenberg RF Gagel V Gilsanz T Guise S Koka LK McCauley J McGowan MD McKee S Mohla DG Pendrys LG Raisz SL Ruggiero DM Shafer L Shum SL Silverman CH Van Poznak N Watts SB Woo E Shane 2007 Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research J Bone Miner Res 22 1479 1491
32. RD Chapurlat PD Delmas 2006 Drug insight: Bisphosphonates for postmenopausal osteoporosis Nat Clin Pract Endocrinol Metab 2 211 219 quiz following 238
33. JP Devogelaer 2000 Treatment of bone diseases with bisphosphonates, excluding osteoporosis Curr Opin Rheumatol 12 331 335
34. CJ Rosen 2005 Clinical practice. Postmenopausal osteoporosis N Engl J Med 353 595 603
35. T Mavrokokki A Cheng B Stein A Goss 2007 Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia J Oral Maxillofac Surg 65 415 423
36. DM Black PD Delmas R Eastell IR Reid S Boonen JA Cauley F Cosman P Lakatos PC Leung Z Man C Mautalen P Mesenbrink H Hu J Caminis K Tong T Rosario-Jansen J Krasnow TF Hue D Sellmeyer EF Eriksen SR Cummings 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 1809 1822
37. RS Weinstein RW Nicholas SC Manolagas 2000 Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip J Clin Endocrinol Metab 85 2907 2912
38. M Kenealy HM Prince 2006 Current status of new drugs for the treatment of patients with multiple myeloma Intern Med J 36 781 789
39. S Pozzi R Marcheselli S Sacchi L Baldini F Angrilli E Pennese G Quarta C Stelitano G Caparotti S Luminari P Musto D Natale C Broglia A Cuoghi D Dini P Di Tonno G Leonardi G Pianezze V Pitini G Polimeno L Ponchio L Masini M Musso M Spriano G Pollastri 2007 Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients Leukemia Lymphoma 48 56 64
40. A Badros D Weikel A Salama O Goloubeva A Schneider A Rapoport R Fenton N Gahres E Sausville R Ord T Meiller 2006 Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors J Clin Oncol 24 945 952
41. BL Riggs AM Parfitt 2005 Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling J Bone Miner Res 20 177 184
42. EF Eriksen 1986 Normal and pathological remodeling of human trabecular bone: three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease Endocr Rev 7 379 408
43. PM Chavassieux ME Arlot C Reda L Wei AJ Yates PJ Meunier 1997 Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis J Clin Invest 100 1475 1480
44. EF Eriksen F Melsen E Sod I Barton A Chines 2002 Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis Bone 31 620 625
45. MR Allen K Iwata R Phipps DB Burr 2006 Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate Bone 39 872 879
46. T Mashiba T Hirano CH Turner MR Forwood CC Johnston DB Burr 2000 Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib J Bone Miner Res 15 613 620
47. RL Jilka RS Weinstein AM Parfitt SC Manolagas 2007 Quantifying osteoblast and osteocyte apoptosis: challenges and rewards J Bone Miner Res 22 1492 1501
48. LI Plotkin JI Aguirre S Kousteni SC Manolagas T Bellido 2005 Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation J Biol Chem 280 7317 7325
49. IR Reid MJ Bolland AB Grey 2007 Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 41 318 320
50. J Wood K Bonjean S Ruetz A Bellahcene L Devy JM Foidart V Castronovo JR Green 2002 Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid J Pharmacol Exp Ther 302 1055 1061
51. M Bezzi M Hasmim G Bieler O Dormond C Ruegg 2003 Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt J Biol Chem 278 43603 43614
52. G Ferretti A Fabi P Carlini P Papaldo P Cordiali Fei S Di Cosimo N Salesi D Giannarelli A Alimonti B Di Cocco G D'Agosto V Bordignon E Trento F Cognetti 2005 Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients Oncology 69 35 43
53. JF Bukowski CC Dascher H Das 2005 Alternative bisphosphonate targets and mechanisms of action Biochem Biophysic Res Commun 328 746 750
54. SS Huja SA Fernandez KJ Hill Y Li 2006 Remodeling dynamics in the alveolar process in skeletally mature dogs Anat Rec A Discov Mol Cell Evol Biol 288 1243 1249
55. M Sato W Grasser N Endo R Akins H Simmons DD Thompson E Golub GA Rodan 1991 Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure J Clin Invest 88 2095 2105
56. Y Azuma H Sato Y Oue K Okabe T Ohta M Tsuchimoto M Kiyoki 1995 Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models Bone 16 235 245
57. SC Manolagas 2000 Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis Endocr Rev 21 115 137
58. AJ Roelofs K Thompson S Gordon MJ Rogers 2006 Molecular mechanisms of action of bisphosphonates: current status Clin Cancer Res 12 6222s 6230s
59. KL Kavanagh K Guo JE Dunford X Wu S Knapp FH Ebetino MJ Rogers RG Russell U Oppermann 2006 The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs Proc Natl Acad Sci USA 103 7829 7834
60. RG Russell 2007 Bisphosphonates: mode of action and pharmacology Pediatrics 119 Suppl 2 S150 S162
61. CT Leu E Luegmayr LP Freedman GA Rodan AA Reszka 2006 Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy Bone 38 628 636
62. G Rodan A Reszka E Golub R Rizzoli 2004 Bone safety of long-term bisphosphonate treatment Curr Med Res Opin 20 1291 1300
63. G Cardaropoli M Araujo J Lindhe 2003 Dynamics of bone tissue formation in tooth extraction sites. An experimental study in dogs J Clin Periodontol 30 809 818
64. T Berglundh I Abrahamsson NP Lang J Lindhe 2003 De novo alveolar bone formation adjacent to endosseous implants Clin Oral Implants Res 14 251 262
65. M Tanzer D Karabasz JJ Krygier R Cohen JD Bobyn 2005 The Otto Aufranc Award: bone augmentation around and within porous implants by local bisphosphonate elution Clin Orthop Relat Res 441 30 39
66. N Amanat M McDonald C Godfrey L Bilston D Little 2007 Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair J Bone Miner Res 22 867 876
67. JV Bagan Y Jimenez J Murillo S Hernandez R Poveda JM Sanchis JM Diaz C Scully 2006 Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases Oral Oncol 42 327 329
68. MH Abu-Id Y Acil J Gottschalk T Kreusch 2006 Bisphosphonate-associated osteonecrosis of the jaw Mund Kiefer Gesichtschir 10 73 81
69. G Store TA Larheim 1999 Mandibular osteoradionecrosis: a comparison of computed tomography with panoramic radiography Dento maxillo facial radiology 28 295 300
70. PJ Bekker DL Holloway AS Rasmussen R Murphy SW Martin PT Leese GB Holmes CR Dunstan AM DePaoli 2004 A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women J Bone Miner Res 19 1059 1066
71. JJ Body T Facon RE Coleman A Lipton F Geurs M Fan D Holloway MC Peterson PJ Bekker 2006 A study of the biological receptor activator of nuclear factor-kappa B ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer Clin Cancer Res 12 1221 1228
72. BT Grant C Amenedo K Freeman RA Kraut 2008 Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases J Oral Maxillofac Surg 66 223 230
73. MK Jeffcoat 2006 Safety of oral bisphosphonates: controlled studies on alveolar bone Int J Oral Maxillofac Implants 21 349 353
74. HL Wang D Weber LK McCauley 2007 Effect of long-term oral bisphosphonates on implant wound healing: literature review and a case report J Periodontol 78 584 594